
  
    
      
        
        Over_IN the_DT past_JJ several_JJ years_NNS ,_, there_EX has_VBZ been_VBN growing_VBG concern_NN about_IN selective_JJ publication_NN
        of_IN clinical_JJ trial_NN results_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. The_DT debate_NN has_VBZ intensified_VBN since_IN New_NNP York_NNP State_NNP Attorney_NNP
        General_NNP Elliot_NNP Spitzer_NNP filed_VBD suit_NN against_IN GlaxoSmithKline_NNP on_IN June_NNP 2_CD ,_, 2004_CD ,_, alleging_VBG that_IN
        the_DT company_NN was_VBD hiding_VBG data_NNS regarding_VBG the_DT efficacy_NN and_CC safety_NN of_IN selective_JJ serotonin_NN
        reuptake_NN inhibitors_NNS in_IN pediatric_JJ patients_NNS with_IN depression_NN [_NN 3_CD ]_NN ._.
        The_DT two_CD most_RBS frequently_RB suggested_VBD remedies_NNS for_IN the_DT selective_JJ reporting_NN of_IN clinical_JJ
        trials_NNS results_NNS have_VBP been_VBN to_TO register_VB all_DT clinical_JJ trials_NNS and_CC to_TO make_VB their_PRP$ results_NNS publicly_RB
        available_JJ ._. Registries_NNP have_VBP been_VBN called_VBN for_IN at_IN least_JJS as_RB far_RB back_RB as_IN 1974_CD ;_: hundreds_NNS have_VBP in_IN
        fact_NN already_RB been_VBN established_VBN [_NN 4_CD ]_NN ._. Shortcomings_NNP of_IN registries_NNS include_VBP the_DT fact_NN that_IN they_PRP
        are_VBP often_RB not_RB coordinated_VBN and_CC that_DT participation_NN is_VBZ often_RB voluntary_JJ and—in_NN cases_NNS where_WRB they_PRP
        are_VBP mandated_VBN by_IN legislation—difficult_NN to_TO enforce_VB ._. For_IN example_NN ,_, ClinicalTrials_NNP ._. gov_NN ,_, a_DT
        registry_NN authorized_VBN by_IN the_DT Food_NNP and_CC Drug_NNP Modernization_NNP Act_NNP of_IN 1997_CD ,_, appears_VBZ not_RB to_TO be_VB
        comprehensive_JJ ._. One_CD study_NN found_VBD that_IN ,_, of_IN 127_CD cancer_NN protocols_NNS sponsored_VBN by_IN pharmaceutical_JJ
        companies_NNS that_WDT met_VBD criteria_NNS for_IN inclusion_NN ,_, only_RB 48_CD %_NN were_VBD in_IN fact_NN submitted_VBN to_TO the_DT registry_NN
        [_NN 5_CD ]_NN ._. Thus_RB ,_, one_PRP can_MD check_VB a_DT number_NN of_IN registries_NNS and_CC still_RB have_VBP little_JJ assurance_NN that_IN all_PDT
        the_DT relevant_JJ trials_NNS of_IN interest_NN have_VBP been_VBN included_VBN ._.
        Increasing_VBG the_DT pressure_NN on_IN pharmaceutical_JJ companies_NNS to_TO include_VB more_JJR trials_NNS in_IN
        registries_NNS ,_, the_DT International_NNP Committee_NNP of_IN Medical_NNP Journal_NNP Editors_NNP has_VBZ announced_VBN that_IN ,_, as_IN a_DT
        condition_NN of_IN considering_VBG a_DT trial_NN for_IN publication_NN ,_, member_NN journals_NNS will_MD require_VB its_PRP$
        registration_NN in_IN a_DT public_JJ trials_NNS registry_NN [_NN 6_CD ]_NN ._. Further_RB ,_, at_IN the_DT American_NNP Medical_NNP Association_NNP
        (_( AMA_NNP )_) Annual_JJ Meeting_VBG of_IN the_DT House_NNP of_IN Delegates_NNPS in_IN June_NNP 2004_CD ,_, the_DT AMA_NNP called_VBD on_IN the_DT
        Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNPS to_TO establish_VB a_DT comprehensive_JJ national_JJ registry_NN ._. In_IN
        September_NNP 2004_CD ,_, an_DT AMA_NNP trustee_NN testified_VBD in_IN a_DT United_NNP States_NNPS Congressional_NNP hearing_NN ,_,
        outlining_VBG elements_NNS necessary_JJ to_TO make_VB such_PDT a_DT registry_NN effective_JJ [_NN 7_CD ]_NN ._. Momentum_NNP for_IN a_DT
        comprehensive_JJ clinical_JJ trials_NNS registry_NN is_VBZ also_RB building_VBG internationally_RB [_NN 8_CD ]_NN ._.
        In_IN this_DT essay_NN ,_, I_PRP argue_VBP that_IN a_DT highly_RB valuable_JJ but_CC underused_JJ registry_NN and_CC results_NNS
        database_NN for_IN US_NNP trials_NNS already_RB exists_VBZ within_IN the_DT Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNPS ,_,
        specifically_RB within_IN the_DT Food_NNP and_CC Drug_NNP Administration_NNP (_( FDA_NNP )_) ._.
      
      
        New_NNP Drug_NNP Applications_NNS
        Before_IN a_DT pharmaceutical_JJ company_NN can_MD conduct_VB a_DT US_NNP trial_NN that_IN it_PRP intends_VBZ to_TO use_VB in_IN support_NN
        of_IN a_DT new_JJ drug_NN application_NN (_( NDA_NNP )_) ,_, it_PRP must_MD first_RB register_VB that_DT trial_NN with_IN the_DT FDA_NNP ._. Because_IN
        the_DT NDA_NNP forms_VBZ the_DT basis_NN for_IN marketing_NN approval_NN ,_, it_PRP seems_VBZ likely_JJ that_IN the_DT percentage_NN of_IN
        industry-sponsored_JJ trials_NNS that_WDT are_VBP registered_VBN with_IN the_DT FDA_NNP is_VBZ very_RB high_JJ ._. This_DT registration_NN
        takes_VBZ the_DT form_NN of_IN an_DT investigational_JJ new_JJ drug_NN (_( IND_NNP )_) application_NN [_NN 9_CD ]_NN ._. The_DT IND_NNP contains_VBZ a_DT
        trial_NN protocol_NN ;_: protocols_NNS for_IN additional_JJ studies_NNS within_IN the_DT same_JJ clinical_JJ trials_NNS program_NN
        are_VBP submitted_VBN as_IN amendments_NNS to_TO the_DT IND_NNP ._. Later_RB ,_, when_WRB the_DT sponsor_NN has_VBZ completed_VBN its_PRP$ clinical_JJ
        trials_NNS program_NN and_CC wishes_VBZ to_TO apply_VB for_IN marketing_NN approval_NN ,_, it_PRP submits_VBZ its_PRP$ NDA_NNP ._.
        The_DT FDA_NNP then_RB begins_VBZ the_DT NDA_NNP review_NN process_NN ,_, during_IN which_WDT a_DT physician_NN ,_, a_DT statistician_NN ,_,
        and_CC a_DT pharmacologist_NN ,_, among_IN others_NNS ,_, generate_VB lengthy_JJ review_NN documents_NNS [_NN 10_CD ]_NN ._. These_DT reviews_NNS
        not_RB only_RB address_VB the_DT sponsor_NN 's_POS analyses_NNS of_IN the_DT data_NNS on_IN pivotal_JJ studies_NNS ,_, but_CC they_PRP often_RB also_RB
        include_VBP reanalyses_NNS by_IN the_DT reviewers_NNS using_VBG raw_JJ data_NNS obtained_VBN from_IN the_DT sponsor_NN ._. These_DT
        analyses_NNS are_VBP conducted_VBN in_IN adherence_NN to_TO the_DT statistical_JJ methods_NNS set_VBN forth_RB a_DT priori_FW in_IN the_DT
        original_JJ trial_NN protocols_NNS ._. (_( By_IN contrast_NN ,_, with_IN most_JJS journal_NN publications_NNS ,_, it_PRP is_VBZ usually_RB not_RB
        possible_JJ for_IN the_DT reader_NN to_TO verify_VB whether_IN what_WP is_VBZ presented_VBN as_IN the_DT main_JJ finding_NN is_VBZ
        consistent_JJ with_IN the_DT original_JJ hypothesis_NNS or_CC whether_IN it_PRP was_VBD a_DT post_NN hoc_FW finding_VBG ._. )_) After_IN the_DT
        primary_JJ reviewers_NNS have_VBP written_VBN their_PRP$ reviews_NNS ,_, shorter_JJR reviews_NNS are_VBP written_VBN by_IN their_PRP$
        superiors_NNS ,_, with_IN the_DT process_NN culminating_VBG in_IN a_DT decision_NN about_IN whether_IN to_TO approve_VB the_DT drug_NN for_IN
        the_DT proposed_VBN indication_NN ._.
      
      
        A_DT Semi-_NNP Public_NNP Database_NNP
        This_DT process_NN occurs_VBZ entirely_RB outside_IN of_IN the_DT public_JJ domain_NN ._. However_RB ,_, in_IN the_DT interest_NN of_IN
        making_VBG the_DT FDA_NNP more_RBR “ transparent_JJ ,_,” and_CC in_IN accordance_NN with_IN the_DT Electronic_NNP Freedom_NNP of_IN
        Information_NNP Act_NNP [_NN 11_CD ]_NN ,_, the_DT FDA_NNP has_VBZ ,_, for_IN the_DT past_JJ several_JJ years_NNS ,_, posted_VBD selected_VBN NDA_NNP reviews_NNS
        for_IN approved_JJ drug–indication_NN combinations_NNS on_IN the_DT FDA_NNP Web_NNP site_NN Drugs_NNS @_IN FDA_NNP
        (_( http_NN :_: /_NN /_NN www_NN ._. accessdata_NN ._. fda_NN ._. gov_NN /_NN scripts_NNS /_NN cder_NN /_NN drugsatfda_NN /_NN index_NN ._. cfm_NN )_) ._. These_DT NDA_NNP review_NN
        documents_NNS are_VBP much_RB more_RBR detailed_JJ than_IN the_DT resulting_VBG package_NN insert_NN and_CC often_RB more_RBR detailed_JJ
        than_IN corresponding_JJ journal_NN publications_NNS ._.
        For_IN example_NN ,_, while_IN the_DT clinical_JJ trials_NNS section_NN of_IN the_DT package_NN insert_NN is_VBZ typically_RB a_DT few_JJ
        paragraphs_NNS long_JJ ,_, the_DT efficacy_NN portion_NN of_IN the_DT clinical_JJ review_NN usually_RB runs_VBZ tens_NNS of_IN pages_NNS ._.
        Because_IN the_DT FDA_NNP is_VBZ made_VBN aware_JJ of_IN all_DT studies_NNS that_IN the_DT sponsor_NN plans_NNS to_TO use_VB in_IN support_NN of_IN
        the_DT NDA_NNP before_IN they_PRP are_VBP conducted_VBN ,_, and_CC thus_RB before_IN there_EX can_MD be_VB any_DT selection_NN based_VBN on_IN
        outcome_NN ,_, these_DT reviews_NNS cover_VBP not_RB only_RB studies_NNS that_WDT are_VBP positive_JJ (_( and_CC more_RBR likely_JJ to_TO be_VB
        published_VBN in_IN journals_NNS )_) ,_, but_CC also_RB studies_VBZ whose_WP$ outcome_NN was_VBD negative_JJ or_CC indeterminate_JJ ._. The_DT
        sidebar_NN gives_VBZ an_DT example_NN of_IN how_WRB NDA_NNP review_NN documents_NNS at_IN the_DT FDA_NNP give_VB valuable_JJ information_NN
        about_IN paroxetine_NN for_IN anxiety_NN disorders_NNS ._.
      
      
        FDA_NNP Reviews_NNP for_IN All_DT Approved_NNP Drugs_NNPS Should_MD Be_VB Made_VBN Public_NNP
        In_IN the_DT examples_NNS discussed_VBN in_IN the_DT sidebar_NN ,_, our_PRP$ having_VBG access_NN to_TO the_DT FDA_NNP review_NN documents_NNS
        allows_VBZ us_PRP to_TO become_VB aware_JJ of_IN ,_, and_CC see_VB beyond_RB ,_, apparent_JJ publication_NN bias_NN ._. It_PRP is_VBZ in_IN the_DT best_JJS
        interest_NN of_IN the_DT public_JJ health_NN for_IN the_DT FDA_NNP to_TO make_VB as_IN many_JJ reviews_NNS available_JJ as_IN possible_JJ ._.
        According_VBG to_TO the_DT FDA_NNP Web_NNP site_NN ,_, “ As_IN FDA_NNP continues_VBZ to_TO be_VB one_CD of_IN the_DT world_NN 's_POS leading_VBG agencies_NNS
        in_IN its_PRP$ emphasis_NN on_IN openness_NN and_CC transparency_NN ,_, it_PRP is_VBZ aware_JJ that_IN making_VBG even_RB more_JJR information_NN
        available_JJ to_TO the_DT public_JJ will_MD further_VB the_DT Agency_NNP 's_POS mission_NN to_TO protect_VB and_CC promote_VB public_JJ
        health_NN and_CC improve_VB its_PRP$ credibility_NN ._. For_IN example_NN ,_, FDA_NNP has_VBZ aggressively_RB implemented_VBN the_DT
        Electronic_NNP Freedom_NNP of_IN Information_NNP Act_NNP …_NN” [_NN 11_CD ]_NN ._.
        Unfortunately_RB ,_, the_DT availability_NN of_IN review_NN documents_NNS on_IN Drugs_NNS @_IN FDA_NNP is_VBZ sporadic_JJ ._. To_TO take_VB
        additional_JJ examples_NNS from_IN psychiatry_NN ,_, NDA_NNP reviews_NNS have_VBP been_VBN posted_VBN on_IN Drugs_NNS @_IN FDA_NNP for_IN some_DT
        approved_VBN drug–indication_NN combinations_NNS ,_, such_JJ as_IN fluoxetine_NN for_IN pediatric_JJ depression_NN ,_, and_CC
        aripiprazole_NN and_CC quetiapine_NN for_IN schizophrenia_NN ._. However_RB ,_, NDA_NNP reviews_NNS for_IN many_JJ other_JJ
        drug–indication_NN combinations_NNS have_VBP not_RB been_VBN posted_VBN :_: the_DT Prozac_NNP Weekly_NNP formulation_NN of_IN
        fluoxetine_NN ,_, clozapine_NN for_IN suicidal_JJ behavior_NN in_IN patients_NNS with_IN schizophrenia_NN or_CC
        schizoaffective_JJ disorder_NN ,_, and_CC quetiapine_NN for_IN mania_NN ,_, among_IN others_NNS ._. A_DT review_NN on_IN paroxetine_NN
        for_IN pediatric_JJ depression_NN ,_, the_DT subject_NN of_IN Elliot_NNP Spitzer_NNP 's_POS suit_NN against_IN GlaxoSmithKline_NNP ,_, is_VBZ
        not_RB posted_VBN ._. This_DT is_VBZ probably_RB because_IN this_DT drug–indication_NN combination_NN was_VBD not_RB approved_VBN ;_: in_IN
        fact_NN ,_, it_PRP is_VBZ possible_JJ that_IN GlaxoSmithKline_NNP did_VBD not_RB file_VB an_DT NDA_NNP to_TO be_VB reviewed_VBN ._. However_RB ,_, I_PRP do_VBP
        not_RB understand_VB why_WRB ,_, in_IN cases_NNS where_WRB NDAs_NNP were_VBD both_DT submitted_VBN and_CC approved_VBN ,_, such_JJ as_IN the_DT ones_NNS
        listed_VBN above_IN ,_, some_DT reviews_NNS are_VBP posted_VBN while_IN others_NNS are_VBP not_RB ._.
        I_PRP therefore_RB suggest_VBP that_IN we_PRP increase_VBP access_NN to_TO the_DT clinical_JJ trials_NNS registry_NN and_CC results_NNS
        database_NN that_IN already_RB exist_VB within_IN the_DT FDA_NNP ._. The_DT agency_NN could_MD expand_VB its_PRP$ implementation_NN of_IN
        the_DT Electronic_NNP Freedom_NNP of_IN Information_NNP Act_NNP and_CC make_VB all_DT NDA_NNP reviews_NNS ,_, at_IN least_JJS for_IN approved_VBD
        NDAs_NNP ,_, available_JJ in_IN the_DT public_JJ domain_NN ._. The_DT act_NN is_VBZ written_VBN into_IN the_DT FDA_NNP portion_NN of_IN the_DT Code_NNP
        of_IN Federal_NNP Regulations_NNPS as_IN follows_VBZ :_: “ The_DT Food_NNP and_CC Drug_NNP Administration_NNP will_MD make_VB the_DT fullest_JJS
        possible_JJ disclosure_NN of_IN records_NNS to_TO the_DT public_JJ ,_, consistent_JJ with_IN the_DT rights_NNS of_IN individuals_NNS to_TO
        privacy_NN ,_, the_DT property_NN rights_NNS of_IN persons_NNS in_IN trade_NN secrets_NNS and_CC confidential_JJ commercial_JJ or_CC
        financial_JJ information_NN” [_NN 12_CD ]_NN ._.
      
      
        Obstacles_NNP and_CC Limitations_NNPS
        There_EX would_MD surely_RB be_VB obstacles_NNS ._. The_DT pharmaceutical_JJ industry_NN would_MD vigorously_RB invoke_VB
        Exemption_NNP 4_CD of_IN the_DT Freedom_NNP of_IN Information_NNP Act_NNP ,_, the_DT exemption_NN for_IN trade_NN secrets_NNS and_CC
        confidential_JJ business_NN information_NN [_NN 13_CD ]_NN ._. However_RB ,_, the_DT FDA_NNP Freedom_NNP of_IN Information_NNP Office_NNP
        already_RB deals_VBZ with_IN confidential_JJ and_CC proprietary_JJ information_NN by_IN redacting_VBG or_CC editing_NN it_PRP out_IN
        of_IN the_DT review_NN documents_NNS before_IN making_VBG them_PRP available_JJ ._. Within_IN the_DT FDA_NNP 's_POS Freedom_NNP of_IN
        Information_NNP Office_NNP ,_, staffing_NN would_MD need_VB to_TO be_VB greatly_RB increased_VBN ._. Some_DT oversight_NN might_MD be_VB
        necessary_JJ to_TO ensure_VB that_IN the_DT taxpaying_VBG public_NN has_VBZ been_VBN granted_VBN the_DT fullest_JJS possible_JJ access_NN
        and_CC that_IN unwarranted_JJ redaction_NN does_VBZ not_RB occur_VB ._. Unless_IN the_DT Freedom_NNP of_IN Information_NNP Act_NNP is_VBZ
        modified_VBN ,_, access_NN would_MD still_RB likely_JJ be_VB limited_VBN to_TO approved_VBD NDAs_NNP ._. Data_NNP would_MD remain_VB
        unavailable_JJ for_IN trials_NNS that_WDT did_VBD not_RB lead_VB to_TO an_DT approved_VBD NDA_NNP ._.
        It_PRP should_MD be_VB clarified_VBN that_IN this_DT resource_NN does_VBZ not_RB compete_VB with_IN proposals_NNS by_IN the_DT AMA_NNP and_CC
        other_JJ groups_NNS for_IN clinical_JJ trial_NN registries—rather_NN ,_, it_PRP complements_VBZ them_PRP ._. The_DT AMA_NNP has_VBZ
        proposed_VBN the_DT creation_NN of_IN a_DT registry_NN that_WDT is_VBZ comprehensive_JJ in_IN scope_NN ._. The_DT FDA_NNP 's_POS registry_NN and_CC
        results_NNS database_NN are_VBP restricted_VBN to_TO those_DT trials_NNS aimed_VBN at_IN supporting_VBG US_NNP marketing_NN approval_NN
        or_CC a_DT change_NN in_IN labeling_VBG in_IN the_DT US_NNP ._. While_IN data_NNS from_IN many_JJ studies_NNS conducted_VBN abroad_RB are_VBP
        submitted_VBN to_TO the_DT FDA_NNP for_IN this_DT purpose_NN ,_, this_DT is_VBZ not_RB the_DT case_NN for_IN drugs_NNS for_IN which_WDT the_DT sponsor_NN
        has_VBZ elected_VBN not_RB to_TO seek_VB approval_NN for_IN marketing_NN in_IN the_DT US_NNP ._. Nor_CC does_VBZ the_DT FDA_NNP review_NN data_NNS from_IN
        most_JJS trials_NNS funded_VBN by_IN other_JJ US_NNP government_NN agencies_NNS ,_, such_JJ as_IN the_DT National_NNP Institutes_NNPS of_IN
        Health_NNP ,_, or_CC by_IN foundations_NNS ._. And_CC drug_NN companies_NNS fund_VBP investigator-initiated_JJ trials_NNS that_WDT are_VBP
        often_RB not_RB registered_VBN with_IN the_DT FDA_NNP ._.
        To_TO make_VB the_DT FDA_NNP review_NN data_NNS more_RBR accessible_JJ and_CC user-friendly_JJ ,_, simple_JJ formatting_VBG changes_NNS
        would_MD be_VB needed_VBN ._. For_IN those_DT (_( few_JJ )_) reviews_NNS that_WDT are_VBP currently_RB posted_VBN on_IN Drugs_NNS @_IN FDA_NNP ,_, one_PRP can_MD
        determine_VB the_DT indication_NN being_VBG evaluated_VBN only_RB after_IN opening_VBG the_DT document_NN and_CC paging_NN through_IN
        it_PRP ._. (_( Descriptive_NNP titles_NNS would_MD be_VB helpful_JJ ,_, and_CC these_DT could_MD be_VB linked_VBN to_TO ClinicalTrials_NNP ._. gov_NN ._.
        Further_RB ,_, the_DT trials_NNS reviewed_VBN could_MD be_VB identified_VBN with_IN a_DT unique_JJ international_JJ identifier_NN ,_, as_IN
        promoted_VBN by_IN the_DT World_NNP Health_NNP Organization_NNP [_NN 14_CD ]_NN ._. )_) Despite_IN the_DT fact_NN that_IN the_DT reviews_NNS are_VBP
        created_VBN in_IN Microsoft_NNP Word_NNP and_CC converted_VBN to_TO PDF_NNP ,_, the_DT versions_NNS that_WDT appear_VBP on_IN the_DT Web_NNP site_NN
        are_VBP no_RB longer_RB in_IN a_DT searchable_JJ text_NN format_NN ._. While_IN the_DT reviews_NNS tend_VBP to_TO be_VB well_RB organized_VBN ,_, the_DT
        posted_VBD versions_NNS are_VBP difficult_JJ to_TO navigate_VB because_IN there_EX is_VBZ no_DT hyperlinked_JJ table_NN of_IN
        contents_NNS ._. In_IN addition_NN to_TO having_VBG these_DT formatting_VBG issues_NNS addressed_VBN ,_, clinicians_NNS and_CC patients_NNS
        might_MD benefit_VB from_IN brief_JJ summaries_NNS ,_, the_DT writing_NN of_IN which_WDT might_MD require_VB the_DT addition_NN of_IN new_JJ
        FDA_NNP staff_NN ._.
      
      
        Conclusion_NNP
        Despite_IN the_DT limitations_NNS of_IN the_DT FDA_NNP 's_POS database_NN ,_, making_VBG it_PRP public_NN is_VBZ a_DT strategy_NN that_WDT could_MD
        be_VB implemented_VBN both_DT rapidly_RB and_CC easily_RB by_IN building_VBG upon_IN existing_VBG infrastructure_NN ._. While_IN we_PRP
        await_VBP the_DT creation_NN of_IN a_DT clinical_JJ trials_NNS registry_NN and_CC results_NNS database_NN that_WDT is_VBZ truly_RB
        comprehensive_JJ ,_, we_PRP already_RB have_VBP at_IN our_PRP$ disposal_NN one_CD that_WDT could_MD serve_VB as_IN a_DT trove_NN of_IN in-depth_JJ
        and_CC unbiased_JJ information_NN on_IN many_JJ ,_, if_IN not_RB most_JJS ,_, drugs_NNS currently_RB marketed_VBN in_IN the_DT US_NNP ._.
      
    
  
